NRIX – nurix therapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia [Yahoo! Finance]
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 [Yahoo! Finance]
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
Form SC 13G/A Nurix Therapeutics, Inc. Filed by: Redmile Group, LLC
Form SC 13G/A Nurix Therapeutics, Inc. Filed by: BAKER BROS. ADVISORS LP
Form SC 13G/A Nurix Therapeutics, Inc. Filed by: SANDS ARTHUR T
Form SC 13G/A Nurix Therapeutics, Inc. Filed by: WASATCH ADVISORS LP
Form SC 13G Nurix Therapeutics, Inc. Filed by: WELLINGTON MANAGEMENT GROUP LLP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.